Table 1.
Patient and tumour characteristics at baseline (whole cohort and stratified according to pathological complete response [pCR] status)
| All | pCR | Non-pCR | ||
|---|---|---|---|---|
| Total, N | 453 | 95 (21.0%) | 358 (79.0%) | |
| Age (years) median (IQR) | 52.5 (43.7–62.1) | 53.1 (43.9–62.6) | 52.4 (43.7–62.1) | |
| BMI (kg/m2), median (IQR) | 25 (23–29) | 25 (23–29) | 25 (23–29) | |
| Menopausal status | Premenopausal | 255 (56.3%) | 52 (54.7%) | 203 (56.7%) |
| Postmenopausal | 198 (43.7%) | 43 (45.3%) | 155 (43.3%) | |
| Any births | No children | 62 (13.7%) | 10 (10.5%) | 52 (14.5%) |
| 1 or more children | 390 (86.1%) | 85 (89.5%) | 305 (85.2%) | |
| Missing | 1 (0.2%) | 0 (0.0%) | 1 (0.3%) | |
| Ever hormone replacement therapy | Yes | 57 (12.6%) | 14 (14.7%) | 43 (12.0%) |
| No | 393 (86.8%) | 81 (85.3%) | 312 (87.2%) | |
| Missing | 3 (0.7%) | 0 (0.0%) | 3 (0.8%) | |
| Mammographic density, BI-RADS | A | 22 (4.9%) | 7 (7.4%) | 15 (4.2%) |
| B | 174 (39.1%) | 40 (42.1%) | 137 (38.3%) | |
| C | 205 (45.3%) | 39 (41.1%) | 166 (46.4%) | |
| D | 49 (10.8%) | 9 (9.5%) | 40 (11.2%) | |
| Tumour size (mm), median (IQR) | 30.0 (22.0–40.0) | 26.5 (20.0–34.5) | 31.5 (22.5–40.0) | |
| Oestrogen receptor | Positive (> 10%) | 274 (60.5%) | 24 (25.3%) | 250 (69.8%) |
| Negative (≤ 10%) | 175 (38.6%) | 70 (73.7%) | 105 (29.3%) | |
| Missing | 4 (0.9%) | 1 (1.1%) | 3 (0.8%) | |
| Progesterone receptor | Positive (> 10%) | 224 (49.4%) | 15 (15.8%) | 209 (58.4%) |
| Negative (≤ 10%) | 224 (49.4%) | 79 (83.2%) | 145 (40.5%) | |
| Missing | 5 (1.1%) | 1 (1.1%) | 4 (1.1%) | |
| HER2 receptor | Positive | 134 (29.6%) | 51 (53.7%) | 83 (23.2%) |
| Negative | 310 (68.4%) | 42 (44.2%) | 268 (74.9%) | |
| Missing | 9 (2.0%) | 2 (2.1%) | 7 (2.0%) | |
| Proliferation (Ki67) | High (> 20%) | 361 (79.7%) | 82 (86.3%) | 279 (77.9%) |
| Low (≤ 20%) | 51 (11.3%) | 3 (3.2%) | 48 (13.4%) | |
| Missing | 41 (9.1%) | 10 (10.5%) | 31 (8.7%) | |
| St. Gallen subtype | Luminal A–like | 45 (9.9%) | 0 (0.0%) | 45 (12.6%) |
| Luminal B–like | 136 (30.0%) | 7 (7.4%) | 129 (36.0%) | |
| HER2-positive | 134 (29.6%) | 51 (53.7%) | 83 (23.2%) | |
| Triple-negative | 113 (24.9%) | 34 (35.8%) | 79 (22.1%) | |
| Missing | 25 (5.5%) | 3 (3.2%) | 22 (6.1%) | |
| Node status | Positive | 307 (67.8%) | 63 (66.3%) | 244 (68.2%) |
| Negative | 76 (16.8%) | 23 (24.2%) | 53 (14.8%) | |
| Missing | 70 (15.5%) | 9 (9.5%) | 61 (17.0%) | |
pCR, pathological complete response; BMI, body mass index; HER2, human epidermal growth factor receptor 2; IQR, interquartile range